fipnet / press — No comments
18
Jun 10
by Matt
Milwaukee, WI (PRWEB) June 17, 2010 — PhysioGenix, Inc. - http://www.physiogenix.com – a leading preclinical CRO, has launched a free web application to aide the study design, planning, and execution. The online tool will allow researchers to hand pick different aspects of a study, from endpoints, assays, tissue samples, and more. PhysioGenix is currently looking for beta users to try out the newly built tool. Feel free to visit http://physiogenix.com/sign-up to register to use this free study design tool and provide feedback.
The study design tool is aimed at gathering vital information for a preclinical rodent study in a matter of minutes. Traditionally within the industry, gathering this information could take weeks of planning, phone calls, and emails. Now with this new study design tool, planning can be completed online in a matter of minutes. Researchers are free to use the tool as much as they would like. Throughout the process, PhysioGenix can be called upon for expertise in designing your specific preclinical study. PhysioGenix has the network of experts, that combined with the study design tool, can help make the planning stages easier, and faster. Continue reading →
fipnet / outsourcing / press — No comments
25
Mar 10
by Josh
PhysioGenix was announced a winner of Company to Watch for 2010. The award is made by the Wisconsin Entrepreneur Network (WEN) with support from the Wisconsin Department of Commerce and the Division of Entrepreneurship and Economic Development at the University of Wisconsin-Extension in association with the Edward Lowe Foundation to celebrate second-stage entrepreneurial companies. Chief Executive Officer Dr. Brian Curry stated, “We are deeply honored to be named as a company to watch in 2010.” Over the past two years the company has under went a major business and scientific reorganization, so the PhysioGenix team views the award as external validation of the progress that has been made. With the new PhysioGenix vision to improve the quality of life through biopharmaceutical solutions by providing preventative, curative and palliative interventions for chronic diseases; the company is excited by the future. Continue reading →
data security / fipnet / outsourcing — No comments
11
Feb 10
by Matt
With the proliferation of many web based applications, blogs, social media sites, media sharing sites, and web-collaboration tools, much of today’s data resides on web servers. With this data architecture, information, materials, and media can be accessed from anywhere in the world with an internet connection. Data can be gathered on demand, with limited usage and storage on hardware and software at the local level. This allows access from multiple people, and does not require everyone to have that piece of data on their personal computer. Can you imagine if everyone downloaded every YouTube video that was watched? There would be massive redundancy on everyones computer, but with cloud computing, every YouTube video simply resides on YouTube’s servers, and can be accessed from their website. While cloud computing has become a business success, it is important to address the information security concerns.
Continue reading →
Uncategorized — 1 comment
29
Jan 10
by Greg
My colleague Brian discussed the FIPNet model in his last post as a structure for drug development and as a model for allocating “core” and “non-core” competencies among various partners to assure that your business has best practices throughout the entire drug development lifecycle.
Today, I would like to talk about how “cloud computing” has accelerated and facilitated the viability of the FIPNet model. If you have used Facebook, Linkedin, Salesforce, Google Apps. or other similar tools on the Internet, then you have used cloud computing. “Cloud computing” in its broadest sense refers to the delivery of applications over the internet, which are accessed via a web browser; the data and software resides on remote servers. At PhysioGenix, we have worked over the last year to move our IT infrastructure into the “cloud”. This has created greater efficiencies, dramatically reduced costs and increased our delivery time of information to our clients.
Continue reading →
fipnet / outsourcing — No comments
22
Jan 10
by Brian
As my colleague Greg discussed last week, Eli Lilly, like many other large pharmaceutical companies, has realized the importance of strategic partnerships from discovery to launch. Current market forces and outdated operating dynamics have forced large pharmaceutical companies to investigate “fully integrated pharmaceutical network” (FIPNets) as a way to gain best practices in non-core competencies. And while the pharmaceutical industry continues to determine the precise nature of an efficient FIPNet model, there is no doubt that strategic partnerships will play an ever-increasing role in drug development.
Continue reading →
Uncategorized — 2 comments
07
Jan 10
by Greg
To begin down the outsourcing path, a business must identify its core competencies. “Core competencies” are skills and knowledge that are central to how a particular business operates and distinguishes itself from other businesses in its industry. Areas of a business that are not “core” have the potential to be outsourced. The ideal outsource partner will be an expert in your non-core competencies; in other words, your outsource partner’s core competencies will be in the areas of your non-core competencies. When the network of internal and external competencies are taken as a whole, your business should be using best practices in all areas.
In a January 5, 2010 article in the Wall Street Journal, Jonathan Rockoff, wrote about Eli Lilly & Co.’s expanded use of outsourcing to run tests on its drug candidates. Lilly has partnered with third-parties to develop a novel rheumatoid arthritis drug. In adopting this approach, Rockoff said that,
“By outsourcing human tests of such a potentially important drug, Lilly is among a crowd of pharmaceutical giants adopting out-of-the-box strategies to revive fallow research-and-development organizations. Lilly is counting on a network of outside contractors to help develop not only the arthritis remedy but several other drugs it hopes start hitting the shelves as early as 2013.”
Continue reading →